Today, the Advanced Coronary Treatment (ACT) Foundation joined Hydro One Inc. (Hydro One) and partners at Archbishop Denis ...

Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

Researchers are exploring how small airway abnormalities in younger smokers could help identify who is at risk of developing COPD and establish how the chronic lung disease progresses.

Gabapentinoids -- pregabalin and gabapentin -- were tied to increased hip fracture risk in older adults. Gabapentinoids -- ...

A new study by Monash University medicine safety experts found the use of gabapentinoids – medicines widely used to treat neuropathic pain – increased the risk of hip fractures, especially in older ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

Amgen, a global biotechnology leader highlighting profound research and development capabilities and biomanufacturing, showcases its latest achievements in the field of innovative medicines under the ...

Amgen, a global biotechnology leader highlighting ... concept advocated by the International Osteoporosis Foundation (IOF). The Power Bone Program achieved the enrolment target of 50,000 patients ...

An international, Phase III clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare ...

Patients with moderate to severe HS experienced sustained symptomatic and quality-of-life improvements with the monoclonal ...

The foundation is also running a social media ... helped by “generous sponsors” that include Merck, AstraZeneca, Amgen, Johnson & Johnson, Daiichi Sankyo and Genentech. Each one has skin ...

We recently published a list of 12 High Growth Large Cap Stocks to Buy Now. In this article, we are going to take a look at ...